CA-DENODO
29.2.2024 08:31:33 CET | Business Wire | Press release
Denodo, a leader in data management, today announced that Forrester Research, Inc. has positioned Denodo as a Leader in The Forrester Wave™: Enterprise Data Fabric, Q1 2024. According to the report, “Denodo is a great fit for customers focusing on an enterprise-wide data fabric strategy to support real-time analytics, customer 360, data engineering, data science, IoT analytics, operational insights, and predictive analytics use cases.” Denodo and 14 other vendors were evaluated across 26 criteria, including current offering, strategy, and market presence.
The complete and complimentary report, published on February 28, is available here.
The Wave revealed that while data fabric traditionally focused on read-only analytical use cases, there is a notable shift towards transactional fabric, with bidirectional read-and-write capabilities to support modern applications such as microservices and real-time customer experience. Today, enterprises are leveraging data fabric to accelerate new and emerging business cases such as customer experience, data science, IoT insights, global transactions, fraud prevention, business 360, and real-time insights.
Forrester VP, Principal Analyst and author of the report, Noel Yuhanna wrote, “Denodo Technologies delivers a world-class data fabric solution. [They have] been a longtime player in data virtualization and now support enterprise data fabric with next-generation data management capabilities. Denodo’s superior data fabric roadmap suggests a focus on advanced data integration, GenAI/LLM, vector search, faster data ingestion, automation, and self-service capabilities.”
Denodo received the highest scores possible in eight criteria, including deployment options, data access and search, data delivery, data processing and persistence, data transformation and lineage, and data integration. The report noted that reference customers like Denodo’s flexible platform, technical support, support for data mesh, data integration, and roadmap.
“This Forrester Research recognition validates, in our opinion, the value of our enterprise data fabric deployments and cloud service. Our customers use the Denodo Platform to establish a common data foundation across the IT corporate infrastructure that enables data products to be created at the speed – and with the agility – required by business users,” said Angel Viña, CEO and Founder at Denodo. “Through this Forrester report, our customers are telling us why Denodo is at the forefront of data management innovation: We simplify data integration through data virtualization technology, which eliminates unnecessary data movement; we accelerate data solutions because we create data ecosystems with true, unified semantics; we speed up time-to-production because we make it faster to access the data in distributed systems; we add self-service capabilities; and we enable new Generative AI applications by helping to create contextualized LLM models that learn from patterns in their own business data.”
With some of the best-in-class and latest innovations, the Denodo Platform:
- Provides IT organizations the flexibility to evolve their data strategies, migrate to the cloud or logically unify data assets without disrupting the business.
- Accelerates data provisioning without requiring costly replication of the data.
- Supports consistent security and governance across multiple systems.
- Enables self-service by giving business users the ability to discover, access and prepare data on their own.
Please Tweet: https://ctt.ac/di1R4
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading data integration, management, and delivery platform using a logical approach to enable self-service BI, data science, hybrid/multi-cloud data integration, and enterprise data services. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across large enterprises and mid-market companies in 30+ industries have received payback in less than 6 months. For more information, visit www.denodo.com or call +1 877 556 2531 (US) / +44 (0) 20 7869 8053 (UK) / +65 6950 7489 (Singapore).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228251918/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom